Comment on “Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer”
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-04-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/13/4/e012221.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850196881876975616 |
|---|---|
| author | Chenglong Wang Shuai An Fang-Tong Liu |
| author_facet | Chenglong Wang Shuai An Fang-Tong Liu |
| author_sort | Chenglong Wang |
| collection | DOAJ |
| format | Article |
| id | doaj-art-02f446f79d124f7480361b58aa8bd6e7 |
| institution | OA Journals |
| issn | 2051-1426 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-02f446f79d124f7480361b58aa8bd6e72025-08-20T02:13:20ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262025-04-0113410.1136/jitc-2025-012221Comment on “Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer”Chenglong Wang0Shuai An1Fang-Tong Liu2Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning, ChinaLiaoning University of Traditional Chinese Medicine, Shenyang, Liaoning, ChinaLiaoning University of Traditional Chinese Medicine, Shenyang, Liaoning, Chinahttps://jitc.bmj.com/content/13/4/e012221.full |
| spellingShingle | Chenglong Wang Shuai An Fang-Tong Liu Comment on “Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer” Journal for ImmunoTherapy of Cancer |
| title | Comment on “Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer” |
| title_full | Comment on “Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer” |
| title_fullStr | Comment on “Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer” |
| title_full_unstemmed | Comment on “Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer” |
| title_short | Comment on “Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer” |
| title_sort | comment on phase 2 study of neoadjuvant durvalumab plus docetaxel oxaliplatin and s 1 with surgery and adjuvant durvalumab plus s 1 for resectable locally advanced gastric cancer |
| url | https://jitc.bmj.com/content/13/4/e012221.full |
| work_keys_str_mv | AT chenglongwang commentonphase2studyofneoadjuvantdurvalumabplusdocetaxeloxaliplatinands1withsurgeryandadjuvantdurvalumabpluss1forresectablelocallyadvancedgastriccancer AT shuaian commentonphase2studyofneoadjuvantdurvalumabplusdocetaxeloxaliplatinands1withsurgeryandadjuvantdurvalumabpluss1forresectablelocallyadvancedgastriccancer AT fangtongliu commentonphase2studyofneoadjuvantdurvalumabplusdocetaxeloxaliplatinands1withsurgeryandadjuvantdurvalumabpluss1forresectablelocallyadvancedgastriccancer |